Loading
A phase 2 trial of BL-M07D1 in HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer is a phase 2 interventional study registered as NCT07678957 by Sichuan Baili Pharmaceutical Co., Ltd., with 120 participants planned, started 2026-08-31 and due to reach its primary completion in 2028-12. Interventions recorded: BL-M07D1 and DS-8201.
Shares HER2-low and HER2-ultralow metastatic breast cancer, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares SystImmune / Sichuan Biokin, HER2-positive breast cancer and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares HER2-low and HER2-ultralow metastatic breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.